MAIA Biotechnology Inc.
MAIA | AMEX
$1.37
+$0.04 (+3.01%)
At close: Sep 22, 2026, 4:00 PM ET
$1.36
-$0.01 (-0.73%)
After-hours:
Sep 22, 2026, 7:33 PM ET
Company Profile
MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.
Key Executives
| Name | Position |
|---|---|
| Vlad Vitoc | Co-Founder, President, Chief Executive Officer & Chairman of the Board of Directors |
| Jeffrey C. Himmelreich | Head of Finance and Principal Financial & Accounting Officer |
| Linda Moreira | Company Secretary |
| Sergei Gryaznov | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 01, 2026 | 4 | Filing |
| Aug 28, 2026 | EFFECT | Filing |
| Aug 26, 2026 | 4 | Filing |
| Aug 24, 2026 | 4 | Filing |
| Aug 21, 2026 | S-3 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 10, 2026 | 10-Q | Quarterly Report |
| Jul 02, 2026 | 4 | Filing |
| Jul 02, 2026 | 4 | Filing |
| Jul 02, 2026 | 4 | Filing |
MAIA Biotechnology Inc.
| Country | United States |
| IPO Date | Jul 27, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Vlad Vitoc |
Contact Details
444 West Lake Street Chicago,
Illinois 60606 United States
Stock Details
| Ticker Symbol | MAIA |
| Exchange | AMEX |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001878313 |
| CUSIP Number | 552641102 |
| ISIN Number | US5526411021 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove MAIA